Synta Pharmaceuticals Appoints John A. McCarthy, Jr. as Senior Vice President Corporate Development and Chief Financial Officer, and Jeremy G. Chadwick, Ph.D. as Vice President, Program Management

Jun 04, 2004, 01:00 ET from Synta Pharmaceuticals Corp.

    LEXINGTON, Mass., June 4 /PRNewswire/ -- Synta Pharmaceuticals Corp., an
 emerging pharmaceutical company, today announced the appointment of John A.
 McCarthy, Jr. as Senior Vice President Corporate Development and Chief
 Financial Officer, and Jeremy G. Chadwick, Ph.D. as Vice President, Program
     "An essential part of growing our business and effectively executing our
 multi-product development program is attracting the type of highly-
 experienced, talented, and high energy individuals we have on our current
 management team and in the new additions announced today," stated Safi
 Bahcall, Ph.D., President and Chief Executive Officer.  "John brings to Synta
 an outstanding history as a seasoned financial executive with broad-based
 healthcare experience, as well as the proven leadership skills needed to help
 manage a rapidly growing business.  John's experience in successfully
 structuring and negotiating complex business partnerships will also add
 strength to our business development initiatives.  I expect John to be a great
 complementary addition to the senior management team at Synta."
     John McCarthy joins Synta from Exact Sciences Corporation where he most
 recently served as Executive Vice President and Chief Financial Officer.  Mr.
 McCarthy joined Exact Sciences in 2000 as a privately-held company and shortly
 thereafter led its successful initial public offering and subsequent public
 financing.  Additionally, Mr. McCarthy was instrumental in developing the
 strategic corporate partnerships and operational infrastructure necessary for
 the company's national launch of its first commercial product in 2003.  Prior
 to Exact Sciences, Mr. McCarthy's healthcare experience included serving as
 President of InfoMedtrics Corporation (privately-held), President of the
 Managed Care Division of Concentra Managed Care, Inc. (publicly-traded), and
 SVP and CFO of MedChem Products, Inc. (publicly-traded).  Additionally, Mr.
 McCarthy's prior experience included serving as an investment banking
 associate with Morgan Stanley.  Mr. McCarthy is a graduate of Lehigh
 University and Harvard Business School.
     "Synta has provided me with a truly unique opportunity to join a company
 with both the breadth and depth in its pipeline to address some of the largest
 market opportunities in the industry," said Mr. McCarthy.  "Additionally, the
 company's strong balance sheet and dedicated investor base provide it with
 considerable flexibility to focus on long-term shareholder value creation.  I
 am very excited to be joining Synta at this important stage of its development
 and look forward to working with the exceptional team that has been built to
     Jeremy Chadwick, Ph.D. joins Synta as Vice President, Program Management
 from Vertex Pharmaceuticals Inc. where he most recently served as Vice
 President, Development Operations.  During his tenure at Vertex, Dr.
 Chadwick's responsibilities were multi-dimensional and included outsourcing,
 planning, new systems and technologies, portfolio management, drug safety,
 medical writing and clinical pharmacology.  Dr. Chadwick's responsibilities
 also included chairing Vertex's Development Advisory Board.  Prior to joining
 Vertex, Dr. Chadwick held various positions including Vice President, US
 Biostatistics and Data Management at Parexel International; Senior Manager,
 Medical Data Sciences Division, Glaxo Group Research; and Chief Operating
 Officer at Foliage Software Systems, a privately-held high-end software
 development company.  Dr. Chadwick obtained both his Masters and Ph.D. in
 Statistics from the University of London, UK.
     "Jeremy's 15-year drug development and program management experience
 working on multiple NDAs in the biopharmaceutical industry will be an
 important contribution to the success of our growing development portfolio,"
 stated Dr. Matthew Sherman, Senior Vice President and Chief Medical Officer.
 Dr. Chadwick added, "I am extremely excited to be joining Synta at such an
 important point in time.  With a rich pipeline, outstanding people and strong
 financial backing we have an opportunity to aggressively move several
 compounds though the clinic. I look forward to contributing to the company's
 success with the entire Synta team."
     About Synta
     Synta Pharmaceuticals is an emerging pharmaceutical company focused on
 discovering, developing, and commercializing breakthrough products for severe
 medical conditions.  Synta has a diverse pipeline of small-molecule
 therapeutics for the treatment of cancer and immune disorders, with its two
 most advanced products in Phase II clinical development.  Synta developed as a
 buyout of the U.S. subsidiary of a large Japanese pharmaceutical company.  As
 a result, Synta has an experienced and successful drug discovery team that has
 worked together for over ten years.  All clinical candidates were developed by
 this team using Synta's chemistry-driven drug discovery platform.  Synta fully
 owns all rights for all of its products.  For more information, please see
      Synta Pharmaceuticals Corp.            Euro RSCG Life NRP
      Safi Bahcall, Ph.D.                    Robert Stanislaro
      President & Chief Executive Officer    Senior Account Executive
      781-541-7177                           212-845-4268

SOURCE Synta Pharmaceuticals Corp.